

Complete if Known Substitute for form 1449/PTO 09/284,683-Conf. #2670 **Application Number INFORMATION DISCLOSURE** Filing Oate June 24, 1999 STATEMENT BY APPLICANT **Gregor CEVC** First Named Inventor 1615 Art Unit (Use as many sheets as necessary) G. S. Kishore Examiner Name 2001377.00123US1 Sheet of Attorney Docket Number

			U.S. PATE	NT DOCUMENTS		
Examinar	0,5	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
pugisis.	Cite No.1	Number-Kind Code <sup>2</sup> ( # Imown)	MM-DD-YYYY	Applicant of Cited Document		
7~	AW1°	US-2001/0012849	08-09-2001	Wechter	·	
7	AX1*	US-2002/0003179	01-10-2002	Verhoff et al.		
	AY1°	US-2002/0012680	01-31-2002	Patel et al.		
_	AZ1*	US-2002/0037877	03-28-2002	Singh		
	AA2*	US-2002/0048596	04-25-2002	CEVC		
	AB2*	US-2002/0106345	08-08-2002	Uhrich et al.		
	AC2	US-2002/0119188	08-29-2002	Niemiec et al.		
	AD2°	US-2002/0147238	10-10-2002	Jerussi et al.		
	AE2*	US-20040071767-A1	04-15-2004	Cevc et al.		
	AF2*	US-20070031483	02-08-2007	Cevc		
	AG2*	US-20070042030-A1	02-22-2007	Cevc		
	AH2*	US-4,369,182	01-18-1983	Ghyczy et al.	·	
	AI2*	US-4,849,224	07-18-1989	Chang et al.		
	AJ2*	US-4,937,182	06-26-1990	Hancock et al.		
_	AK2*	US-4,937,254	06-26-1990	Sheffield et al.		
	AL2*	US-4,983,395	01-08-1991	Chang et al.		
	AM2*	US-5,202,125	04-13-1993	Ebert et al.		
$\neg \vdash$	AN2*	US-5,209,720	05-11-1993	Unger		
$\neg$	A02*	US-5,244,678	09-14-1993	Legros et al.		
	AP2*	US-5,460,820	10-24-1995	Ebert et al.		
	AQ2*	US-5,585,109	12-17-1996	Hayward et al.		
	AR2°	US-5,614,178	03-25-1997	Bloom et al.		
	AS2*	US-5,681,849	10-08-1997	Richter et al.		
	AT2°	US-5,783,208	07-21-1998	Venkateshwaran et al.		
	AU2*	US-5,874,095	02-23-1999	Deckner et al.		
$\neg \vdash$	AV2*	US-5,891,472	04-06-1999	Russell		
_	AW2*	US-6,277,892	08-21-2001	Deckner et al.		
	AX2*	US-6,577,880	06-10-2003	Ishida et al.		
	AY2	US-6,797,276	09-28-2004	Glenn et al.		
<del>,</del>	AZ2	US-6,868,686-A1	03-22-2005	Ueda et al.		
100	AA3*	US-RE 33273		Speaker		

		FOREIG	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
tnitials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>3</sup> (# known)		Applicant of Cited Document	Or Relevant Figures Appear	1
1~	BS	JP-2006131597 (English Language Abstract)	05-02-2006	Hisamitsu Pharmaceut CO inc		
	BT	WO-90/09385	08-23-1990	The Liposome Company Inc		
	ΒU	WO-90/11065	10-04-1990	Theratech, Inc.		
	в۷	WO-91/01146	02-07-1991	Praxis Biolog Inc		
	₿W	WO-92/04009	03-19-1992	Univ London Pharmacy		oxdot
	вх	WO-96/19205	06-27-1996	Theratech, Inc.		
7/4	BY	WO-98/24407 (English Language Abstract)	06-11-1998	L'Oreal		

Examiner Signature	Keple	Date Considered	81	0)	
6274578				-	

2001377.00123US1

Substitute for form 1449/PTO

Complete If Known

Application Number 09/284,683-Conf. #2670

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete If Known

Application Number 09/284,683-Conf. #2670

Filing Date June 24, 1999

First Named Inventor Gregor CEVC

Art Unit 1615

Examiner Name G. S. Kishore

Attorney Docket Number

		BZ	WO-00/44349	08-03-2000	IDEA AG	
$\Box$	70	BA1	WO-01/000247	01-04-2001	The Liposome Company, Inc	
		BB1	WO-02/32398	04-25-2002	KOHANE, et al	
		BC1	WO-02/058670	08-01-2002	CHASIN, et al	
		BD1	WO-04/032900	04-22-2004	IDEA AG	
Γ,		BE1	WO-05/063213	07-14-2005	Biodelivery Sciences International, Inc	
	W	BF1	WO-06/050926	05-18-2006	IDEA AG	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "CITE NO.: Those application(e) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was fited after June 30, 2003 or is available in the IFW. "Applicant's unique citation designation number (optional)." See Kinds Codes of USPTO Petent Documents at <a href="https://www.isolo.gop">https://www.isolo.gop</a> or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document." Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to piace a check mark here if English language Translation is attached."

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
In	СК	Almeida et al., "Nasal delivery of vaccines," Journal of Drug Targeting, Vol 3, No 6, pp. 455-67 (1996)	
	CL	Byas-Smith et al., "Transdermal clonidine compared to placebo in painful diabetic neuropathy using two stage 'enriched enrollment' design," Pain, Vol 60, pp. 267-274 (1995)	
	СМ	Castillo et al., "Glucocorticoids Prolong Rat Sciatic Nerve Blockade In Vivo from Bupivacaine Microspheres," Anesthesiology, Vol 85, No 5, pp. 1157-66 (1996)	
	CN	Cevc et al., "Phospholipids handbook", Marcel Dekker, Inc., New York, Basel, Hong Kong, pp. 375-376 and 404 (1993)	
	СО	Claims filed February 4, 2003, in connection with U.S. Patent Application No. 10/357,617 (U.S. Patent Publication No. US 2004/0071767 A1), under examination by Examiner Kishore of the USPTO.	
	СР	Claims filed October 20, 2006, in connection with U.S. Patent Application No. 10/357,617 (U.S. Patent Publication No. US 2004/0071767 A1), under examination by Examiner Kishore of the USPTO.	
	CQ	Claims filed January 22, 2007, in connection with U.S. Patent Application No 10/037,480 (U.S. Patent Publication No. US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO	
	CR	Claims filed March 20, 2006, in connection with U.S. Patent Application No 10/037,480 (U.S. Patent publication No. US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO	
	cs	Claims filed September 21, 2005, in connection with U.S. Patent Application No. 10/037,480 (U.S. Patent Publication No. US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO	
	СТ	Claims filed October 20, 2004, in connection with U.S. Patent Application No 10/037,480 (U.S. patent Publication No. US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO	
/	CU	Claims filed January 4, 2002, in connection with U.S. Patent Application No 10/037,480 (U.S. Patent Publication No. US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO	
	cv	Claims filed February 26, 2007, in connection with U.S. Patent Application No. 10/984,450	

Examiner Signature	Kuph	Date Considered	8	0	

Sheet

Complete If Known Substitute for form 1449/PTO 09/284,683-Conf. #2670 **Application Number INFORMATION DISCLOSURE** Filing Date June 24, 1999 STATEMENT BY APPLICANT First Named Inventor Gregor CEVC Art Unit 1615 (Use às many sheets as necessary) Examiner Name G. S. Kishore 4 2001377.00123US1 Sheet of Attorney Docket Number

CX CY	Of the USPTO  Claims filed May 31, 2006, in connection with U.S. Patent Application No 10/984,450 (U.S. Patent Publication No US 2005/0123897 A1), Under examination by Examiner Fortuna of the USPTO  Claims filed May 31, 2005, in connection with U.S. Patent Application No 10/984,450 (U.S. Patent Publication No US 2005/0123897 A1), under examination by Examiner Fortuna of the USPTO  Claims filed May 12, 2004, in connection with U.S. Patent Application No. 10/357,618 (U.S. Patent Publication No. 2004/0105881 A1), under examination by Examiner Ghali of the USPTO  Claims presently pending in U.S. Patent Application No 09/890,335, under examination by
	Patent Publication No US 2005/0123897 A1), under examination by Examiner Fortuna of the USPTO  Claims filed May 12, 2004, in connection with U.S. Patent Application No. 10/357,618 (U.S. Patent Publication No. 2004/0105881 A1), under examination by Examiner Ghali of the USPTO  Claims presently pending in U.S. Patent Application No 09/890,335, under examination by
CY	Patent Publication No. 2004/0105881 A1), under examination by Examiner Ghali of the USPTO  Claims presently pending in U.S. Patent Application No 09/890,335, under examination by
CZ	Examiner Gangle of the USPTO
CA1	Claims presently pending in U.S. Patent Application No 09/890,371, under examination by Examiner Hissong of the USPTO
CB1	Copy of International Search Report for International Patent Application No. PCT/EP2005/011986. (July 4, 2006).
CC1	Definition of MicrobicIde, Wikipedia, The Free Online encyclopedia (2007)
, CD1	Edwards, et al., Effects of Triton X-100 on Sonicated Lecithin Vesicles, Langmuir, Vol. 5, pages 472-475 (1989).
CE1	Frantzen et al., * Assessing the accuracy of routine Photon Correlation Spectroscopy Analysis of Heterogeneous Size Distributions, * AAPS PharmSciTech, Vol 4, No 3, Article 36, pp. 1-9 (2003)
CF1	Glen et al, "Skin immunization made possible by cholera toxin 'letterl", Nature, GB, MacMillan Journal LTD., London, Vol 391, no 6670, pp. 851 (Feb 1998)
CG1	Golden et al., "Role of Stratum Comeum Lipid Fluidity Transdermal Drug Flux," on Journal of Pharmaceutical Sciences Vol. 76, No. 1, January 1987, American Pharmaceuticals Association, pp. 25-28.
CH1	Grahame R, "Transdermal non-steroidal anti-inflammatory agents," BJCP, Vol 49, No1, pp. 33-35 (Jan-Feb 1995)
CI1	Holzbach RT, "Detection of Vesicles in native and model Biles by Morphological and other structural Techniques: applications and limitations," Hepatology, Sep12 (3 Pt 2), pp. 106S-112S (1990)
CJ1	tto, Yoshimasa et al. "Percutaneous Absorption of Acemetacin from a Membrane Controlled Transdermal System and Prediction of the Disposition of the Drug in Rats." Biol. Pharm. Bull., 16(6):583-588. (1993).
CK1	Lehmann, J. et al. "Analgesic and anti-inflammatory efficacy of IDEA-070 in UVB-induced sunburn." Journal of the European Academy of Dermatology and Venereology, 18(S2):167-168. (October 2004).
CL1	Merck Index: 10th Edition. pp. 779-780. (1983).
CM1	Office Action issued April 11, 2007, in connection with U.S. Patent Application No. 10/037,480 (U.S. Patent Publication No. US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO.
CN1	Office Action issued December 19, 2005, in connection with U.S. Patent Application No. 10/037,480 (U.S. Patent Publication No. US 2003/0099694 A1), under examiner by Examiner Fortuna of the USPTO
CO1	Office Action issued December 28, 2006, in connection with U.S. Patent Application No. 10/357,618 (U.S. Patent Publication No. 2004/0105881 A1) under examination by Examiner Ghali of the USPTO.

Examiner Signature	Kull	•	Date Considered	8	07	

6274578

Sui	Complete if Known  Application Number 09/284,683-Conf. #2670  INFORMATION DISCLOSURE Filling Date June 24, 1999  STATEMENT BY APPLICANT First Named Inventor Gregor CEVC				
				Application Number	09/284,683-Conf. #2670
	<b>NFORMATION</b>	N DI	SCLOSURE	Filing Date	June 24, 1999
S	STATEMENT BY APPLICANT			First Named Inventor	Gregor CEVC
				Art Unit	1615
	(Use as many sh	eets as	necessary)	Examiner Name	G. S. Kishore
Sheet	. 4	of	4	Attorney Docket Number	2001377.00123US1

lu	CP1	Office Action issued January 19, 2007, in connection with U.S. Patent Application No. 10/357,617 (U.S. Patent Publication No. US 2004/0071767 A1), under examination by Examiner Kishore of the USPTO.
	CQ1	Office Action issued March 30, 2005, in connection with the U.S. Patent Application No. 10/037,480 (U.S. Patent Publication No U.S. 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO
	CR1	Office Action issued May 30, 2006, in connection with U.S. Patent Application No. 10/357,617 (U.S. Patent Publication No. US 2004/0071767 A1), under examination by Examiner Kishore of the USPTO.
	CS1	Office Action issued on August 28, 2006, in connection with U.S. Patent Application No 10/984,450 (U.S. Patent Publication No US 2005/0123897 A1), under examination by the Examiner Fortuna of the USPTO
	CT1	Office Action issued on February 7, 2006, in connection with U.S. Patent Application No 10/984,450 (U.S. Patent Publication No US 2005/0123897 A1), under examination by Examiner Fortuna of the USPTO
	CU1	Office Action issued on May 16, 2007, in connection with U.S. Patent Application No 10/984,450 (U.S. Patent Publication No. US 2005/0123897 A1), under examination by Examiner Fortuna of the USPTO.
	CV1	Office Action issued on October 16, 2003, in connection with U.S. Patent Application No 10/037,480 (U.S. Patent Publication No US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO
	CW1	Office Action issued September 20, 2006, in connection with U.S. Patent Application No. 10/037,480 (U.S. Patent Publication No US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO
	CX1	Ogiso, Taro et al. "Membrane-Controlled Transdermal Therapeutic System Containing Clonazepam and Anticonvulsant Activity after its Application." Chem. Pharm. Bull., 37(2):446-449. (1989).
	CY1	Paul et al., "Non Invasive administration of protein antigens: transdermal Immunization with bovine serum albumin in transfersomes," Vaccine Research, Vol 4, No 3, pp. 145-164 (1995)
	CZ1	Paul et al., "Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes," Vaccine, Vol 16, No 2-3, pp. 188-195 (Jan 1998)
	CA2	Price, "A Review of the Factors Influencing the Penetration of Pesticides through Plant Leaves," I.C.I. Ltd, Plant Protection Division, Jealott's Hill Research station, Bracknell, Berkshire RG12 6EY, UK, pgs. 237-252.
	CB2	Product Information, "Polysorbate 80 VG" (2004)
	CC2	Product Information, "Tween 80 Pure" (2004)
	CD2	Ranade V., "Drug Delivery Systems.6. Transdermal Drug Delivery," J. Clin Pharmacol, Vol 31, pp. 401-418 (1991)
.	CE2	Swenson, E. Scott and William J. Curatolo. "Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity." Advanced Drug Delivery Reviews, 8:39-92. (1992).
	CF2	Trotta, M. et al. "Deformable liposomes for dermal administration of methotrexate."  International Journal of Pharmaceutics, 270:119-125. (February 11, 2004).
	CG2	Trotta, M. et al. "Elastic liposomes for skin delivery of dipotassium glycyrrhizinate."  International Journal of Pharmaceutics, 241(2):319-327. (July 25, 2002).
	CH2	Wess, L. *Down, down, deeper and down.* Biocentury, The Bernstein Report on BioBusiness, 12(22):A11-A12. (May 17, 2004).
1/1	CI2	Yuan, et al., "Cationic Liposome and Gene Transfer," Progress in Physiological Science, 28(2), pp. 163-165, 1997.
xamine	r	Considered 807